These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

388 related articles for article (PubMed ID: 25529832)

  • 1. Neurotoxicity in ovarian cancer patients on Gynecologic Oncology Group (GOG) protocol 218: characteristics associated with toxicity and the effect of substitution with docetaxel: an NRG Oncology/Gynecologic Oncology Group study.
    Chase DM; Huang H; Foss CD; Wenzel LB; Monk BJ; Burger RA
    Gynecol Oncol; 2015 Feb; 136(2):323-7. PubMed ID: 25529832
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improvement of paclitaxel-induced neuropathy by substitution of docetaxel for paclitaxel.
    Rose PG; Smrekar M
    Gynecol Oncol; 2003 Nov; 91(2):423-5. PubMed ID: 14599877
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Docetaxel versus paclitaxel for adjuvant treatment of ovarian cancer: case-control analysis of toxicity.
    Hsu Y; Sood AK; Sorosky JI
    Am J Clin Oncol; 2004 Feb; 27(1):14-8. PubMed ID: 14758127
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma.
    Vasey PA; Jayson GC; Gordon A; Gabra H; Coleman R; Atkinson R; Parkin D; Paul J; Hay A; Kaye SB;
    J Natl Cancer Inst; 2004 Nov; 96(22):1682-91. PubMed ID: 15547181
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase 3 trial (NRG Oncology-Gynecologic Oncology Group protocol 240).
    Penson RT; Huang HQ; Wenzel LB; Monk BJ; Stockman S; Long HJ; Ramondetta LM; Landrum LM; Oaknin A; Reid TJ; Leitao MM; Method M; Michael H; Tewari KS
    Lancet Oncol; 2015 Mar; 16(3):301-11. PubMed ID: 25638326
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial.
    Coleman RL; Brady MF; Herzog TJ; Sabbatini P; Armstrong DK; Walker JL; Kim BG; Fujiwara K; Tewari KS; O'Malley DM; Davidson SA; Rubin SC; DiSilvestro P; Basen-Engquist K; Huang H; Chan JK; Spirtos NM; Ashfaq R; Mannel RS
    Lancet Oncol; 2017 Jun; 18(6):779-791. PubMed ID: 28438473
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I study with an expanded cohort to assess feasibility of intravenous docetaxel, intraperitoneal carboplatin and intraperitoneal paclitaxel in patients with previously untreated ovarian, fallopian tube or primary peritoneal carcinoma: a Gynecologic Oncology Group study.
    Gould N; Sill MW; Mannel RS; Thaker PH; DiSilvestro PA; Waggoner SE; Yamada SD; Armstrong DK; Fracasso PM; Walker JL
    Gynecol Oncol; 2012 Dec; 127(3):506-10. PubMed ID: 22943879
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Universal tolerance of nab-paclitaxel for gynecologic malignancies in patients with prior taxane hypersensitivity reactions.
    Maurer K; Michener C; Mahdi H; Rose PG
    J Gynecol Oncol; 2017 Jul; 28(4):e38. PubMed ID: 28541630
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A cost-utility analysis of NRG Oncology/Gynecologic Oncology Group Protocol 218: incorporating prospectively collected quality-of-life scores in an economic model of treatment of ovarian cancer.
    Cohn DE; Barnett JC; Wenzel L; Monk BJ; Burger RA; Straughn JM; Myers ER; Havrilesky LJ
    Gynecol Oncol; 2015 Feb; 136(2):293-9. PubMed ID: 25449568
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: a Gynecologic Oncology Group study.
    Rose PG; Blessing JA; Ball HG; Hoffman J; Warshal D; DeGeest K; Moore DH
    Gynecol Oncol; 2003 Feb; 88(2):130-5. PubMed ID: 12586591
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A pilot study of docetaxel-carboplatin versus paclitaxel-carboplatin in Japanese patients with epithelial ovarian cancer.
    Mori T; Hosokawa K; Kinoshita Y; Watanabe A; Yamaguchi T; Kuroboshi H; Kato Y; Yasuda J; Fujita H; Nakata Y; Honjo H
    Int J Clin Oncol; 2007 Jun; 12(3):205-11. PubMed ID: 17566844
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improved outcomes with dose-dense paclitaxel-based neoadjuvant chemotherapy in advanced epithelial ovarian carcinoma.
    Becker DA; Thomas ED; Gilbert AL; Boone JD; Straughn JM; Huh WK; Bevis KS; Leath CA; Alvarez RD
    Gynecol Oncol; 2016 Jul; 142(1):25-29. PubMed ID: 27130405
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dose-dense paclitaxel versus docetaxel following FEC as adjuvant chemotherapy in axillary node-positive early breast cancer: a multicenter randomized study of the Hellenic Oncology Research Group (HORG).
    Saloustros E; Malamos N; Boukovinas I; Kakolyris S; Kouroussis C; Athanasiadis A; Ziras N; Kentepozidis N; Makrantonakis P; Polyzos A; Christophyllakis C; Georgoulias V; Mavroudis D
    Breast Cancer Res Treat; 2014 Dec; 148(3):591-7. PubMed ID: 25399229
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase I study with an expanded cohort to assess the feasibility of intravenous paclitaxel, intraperitoneal carboplatin and intraperitoneal paclitaxel in patients with untreated ovarian, fallopian tube or primary peritoneal carcinoma: a Gynecologic Oncology Group study.
    Gould N; Sill MW; Mannel RS; Thaker PH; Disilvestro P; Waggoner S; Yamada SD; Armstrong DK; Wenzel L; Huang H; Fracasso PM; Walker JL
    Gynecol Oncol; 2012 Apr; 125(1):54-8. PubMed ID: 22155262
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of Taxane Type With Patient-Reported Chemotherapy-Induced Peripheral Neuropathy Among Patients With Breast Cancer.
    Mo H; Yan X; Zhao F; Teng Y; Sun X; Lv Z; Cao M; Zhao J; Song G; Pan B; Li H; Zhai J; Xu B; Ma F
    JAMA Netw Open; 2022 Nov; 5(11):e2239788. PubMed ID: 36322088
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patient reported outcomes of a randomized, placebo-controlled trial of bevacizumab in the front-line treatment of ovarian cancer: a Gynecologic Oncology Group Study.
    Monk BJ; Huang HQ; Burger RA; Mannel RS; Homesley HD; Fowler J; Greer BE; Boente M; Liang SX; Wenzel L
    Gynecol Oncol; 2013 Mar; 128(3):573-8. PubMed ID: 23219660
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Taxane-induced peripheral neuropathy and health-related quality of life in postoperative breast cancer patients undergoing adjuvant chemotherapy: N-SAS BC 02, a randomized clinical trial.
    Shimozuma K; Ohashi Y; Takeuchi A; Aranishi T; Morita S; Kuroi K; Ohsumi S; Makino H; Katsumata N; Kuranami M; Suemasu K; Watanabe T; Hausheer FH
    Support Care Cancer; 2012 Dec; 20(12):3355-64. PubMed ID: 22584733
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outpatient platinum-taxane intraperitoneal chemotherapy regimen for ovarian cancer.
    Seamon LG; Carlson MJ; Richardson DL; Cohn DE; Fowler JM; Copeland LJ; O'Malley DM
    Int J Gynecol Cancer; 2009 Oct; 19(7):1195-8. PubMed ID: 19823054
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase II study of docetaxel weekly in combination with carboplatin every three weeks as first line chemotherapy in stage IIB-IV epithelial ovarian cancer: neurological toxicity and quality-of-life evaluation.
    Sorbe B; Graflund M; Nygren L; Horvath G; Swahn M; Boman K; Bangshöj R; Lood M; Malmström H
    Int J Oncol; 2012 Mar; 40(3):773-81. PubMed ID: 22159569
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Farletuzumab (a monoclonal antibody against folate receptor alpha) in relapsed platinum-sensitive ovarian cancer.
    Armstrong DK; White AJ; Weil SC; Phillips M; Coleman RL
    Gynecol Oncol; 2013 Jun; 129(3):452-8. PubMed ID: 23474348
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.